Table of Contents
Cardiovascular Drugs That Prolong The QT Interval
Issues
I. Approval for Atrial Arrhythmias
d, l,-Sotalol
Sotalol: Mean QTc Prolongatation and TdP
Sotalol: Effect on Mortality
Sotalol: Effect on Mortality
Dofetilide
Dofetilide: Dose-Effect on TdP and VF*
Dofetilide: Mortality Effect in High-Risk Population
Dofetilide: Mortality in Supraventricular Arrhythmia Trials
Dofetilide: Dose-Adjustment to Minimize Cardiac Toxicity
Dofetilide: Effect of Dose-Adjusting for Renal Fxn
Dofetilide/ Sotalol Summary
II. Approval As Second-Line Therapy
Bepridil
Bepridil
Bepridil: Summary
Division of Cardio-Renal Drug Products Summary/Conclusions
Division of Cardio-Renal Drug Products Summary/Conclusions
Division of Cardio-Renal Drug Products Summary/Conclusions
|